Pulmonary function abnormalities are common in thalassemia patients undergoing hypertransfusion therapy. Most patients exhibit hypoxemia and small airway disease, indicating significant lung function impairment.
Area of Science:
Pulmonary Medicine
Hematology
Cardiorespiratory Physiology
Background:
Thalassemia is a genetic blood disorder requiring chronic blood transfusions.
Hypertransfusion programs aim to manage severe thalassemia but may have systemic effects.
Lung function in thalassemia patients on chronic transfusion therapy is not fully understood.
Purpose of the Study:
To assess pulmonary function abnormalities in thalassemia patients on a hypertransfusion program.
To identify specific patterns of lung dysfunction in this patient cohort.
To explore potential correlations between pulmonary function and disease/treatment factors.
Main Methods:
Conducted comprehensive pulmonary function tests (PFTs) on 12 thalassemia patients.
Included spirometry, lung volumes (body plethysmography), gas exchange (single-breath nitrogen washout, diffusing capacity), and arterial blood gases.
Evaluated parameters for abnormalities indicative of airway obstruction, hyperinflation, and gas exchange impairment.
Main Results:
Only one of 12 patients had normal pulmonary function.
Ten patients presented with resting arterial hypoxemia.
Abnormalities included increased residual volume (5/12), abnormal slope of phase III nitrogen washout (5/12), and decreased maximal expiratory flow rates suggesting small airway disease (4/12).
Total lung capacity and single-breath carbon monoxide diffusing capacity were generally normal.
Pulmonary function abnormalities did not correlate with age or iron levels from transfusions.
Conclusions:
Thalassemia patients on hypertransfusion therapy frequently exhibit significant pulmonary dysfunction.
Small airway obstruction, hyperinflation, and hypoxemia are key findings.
These abnormalities may stem from the underlying thalassemia, iron overload in the lungs, or other contributing factors.